Aktis Oncology, Inc (AKTS) Stock Price Today & Analysis

AKTS
AKTS company logo
Loading...
Chart by TradingView

Valuation

Market cap$1.04B
Price-to-sales ratioN/A
Price-to-book valueN/A
Price-earnings ratio-24.60
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A

Earnings Per Share

Earnings Per Share$-16.42

Income Statement

Average volume1,008,901
EBITDAN/A
1 year high (52w)$29.16
1 year low (52w)$19.02

Dividend

Dividend yield0.00%

Solvency

Debt-to-equity ratioN/A

About Aktis Oncology, Inc

The company is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that have demonstrated transformative survival outcomes and meaningful quality-of-life benefits through the delivery of radioisotopes to solid tumors. These leading products, which target prostate-specific membrane antigen (PSMA) or the somatostatin-2 receptor, are each approved for only a single tumor type, yet have achieved substantial commercial adoption and have become foundational pillars of modern cancer treatment. Despite these advances, the company believes that the radiopharmaceutical field remains in its early stages, with many emerging companies continuing to focus primarily on these same two biological targets. In contrast, the company sees a significant opportunity to expand the range of cancer patients who may benefit from targeted radiopharmaceuticals by developing next-generation technologies designed to broaden the spectrum of tumor targets for which a potent alpha-emitting radioisotope payload can be delivered safely and effectively.

FAQ

You can easily purchase Aktis Oncology, Inc (AKTS) shares through the Gotrade app. Simply download the app, set up your account, fund it, and then search for the 'AKTS' ticker to begin your investment journey.
At Gotrade, you can kickstart your investment in Aktis Oncology, Inc with as little as $1.
Absolutely. Brokerage services on Gotrade Indonesia are provided by PT Valbury Asia Futures, a licensed futures and commodities broker registered with and supervised by the Indonesian Financial Services Authority (OJK).
Yes. Gotrade provides access to U.S. stocks from Indonesia through fully backed shares. This is facilitated through a cross-border order routing scheme for foreign stock derivative contracts (PALN), in accordance with regulations from Bappebti (the Commodity Futures Trading Regulatory Agency).
When you trade, you enter into a contract with PT Valbury Asia Futures (Valbury), a Bappebti-registered broker in Indonesia. Valbury, in turn, fully backs its contracts 1-for-1 with Alpaca Securities LLC, a FINRA-licensed broker-dealer in the United States. For every share (or fraction thereof) you hold on Gotrade, a corresponding share is held by Valbury in a separate, segregated brokerage account at Alpaca Securities LLC.
AppLogo

Buy saham AKTS
di Gotrade

AppLogo

Gotrade